Emyria (ASX: $EMD) introduces new Empax Centre

Emyria Limited (ASX: $EMD) has proudly announced the opening of the Empax Centre, a cutting-edge facility dedicated to the delivery and development of new treatments for mental health, particularly focusing on MDMA-assisted therapy for individuals with difficult-to-treat PTSD. The company aims to achieve operational profitability by the second half of 2024 and has plans for national and global scalability through further site expansion.

Executive Commentary on Empax Centre

The Empax Centre demonstrates Emyria's commitment to lead the way in mental health innovation within the regulatory frameworks set by the TGA. Our extensive research and development efforts, particularly in MDMA-assisted therapy for PTSD, have shaped our strategic approach towards scalability and profitability - essential for the widespread adoption and success of these innovative treatments. This new facility not only signifies our commitment to improving mental health care but also highlights our firm belief in the transformative potential of our treatments.

Summary of Emyria's Empax Centre Announcement

Emyria has opened the Empax Centre, a state-of-the-art facility dedicated to the delivery and development of new treatments for mental health, with a specific focus on MDMA-assisted therapy for difficult-to-treat PTSD. The company aims to achieve operational profitability by the second half of 2024 and has plans for national and global scalability through further site expansion. The Centre is expected to substantially increase the company's care delivery and research revenues and directly support the innovation pipeline of new care models and proprietary drug therapies. Additionally, the Centre is designed as a blueprint for scalable mental health treatment nationwide and globally, with the potential to support multiple revenue streams from direct patient care and sponsored clinical research. Emyria's long-term innovation pipeline involves actively developing new and improved care models as well as novel drug treatments inspired by MDMA. The company is also advancing an ambitious MDMA analogue development program with global partners, aiming to become a new treatment for PTSD.